Bicycle Therapeutics Ltd (BCYC)
Bicycle Therapeutics plc is a clinical-stage biotechnology company headquartered in Cambridge, United Kingdom. The listed security on NASDAQ is a depositary receipt tied to the company’s common stock, rather than ordinary local equity. The company is focused on developing therapies for diseases that remain underserved by current treatment options in the United States and the United Kingdom.
Its pipeline includes zelenectide pevedotin, a bicycle toxin conjugate in phase II trials for tumors with high nectin-4 expression; nuzefatide pevedotin, a BTC in phase I/II studies for EphA2-expressing tumors; BT7480, a tumor-targeted immune cell agonist molecule in phase I/II development; and BT1702, a theranostic BRC molecule targeting MT1-MMP that is in IND-enabling work. Bicycle Therapeutics also has preclinical programs in CNS disease, neuromuscular disease, and radiopharmaceuticals, and it collaborates with companies including Bayer Consumer Care, Novartis, Ionis Pharmaceuticals, Genentech, and AstraZeneca.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BCYC
|
$5.25
|
40.7% Upside
|
Undervalued
|
$9.50
|
154.7% Upside
|
Bargain
|
Weak
|
0.0%
|
October 29, 2026
|
0.5x
|
4.3x
|
261.1 M
|
-234.3 M
|
5.5%
|
11.1%
|
6.8
|
109.4%
|
